Asymmetric Isomerization of N,N-Diethylgeranylamine in (−)-Menthol Production

BINAP-Rh catalyzes the asymmetric isomerization of N,N-diethylgeranylamine to the chiral enamine intermediate in the Takasago (−)-menthol process. The catalyst is generated from [Rh(COD)Cl]₂ and (R)-BINAP in degassed tetrahydrofuran under nitrogen, then applied at substrate/catalyst molar ratios reported in industrial literature between 5,000 and 20,000, corresponding to rhodium loadings of 0.005–0.02 mol%; the BINAP-to-rhodium molar ratio is maintained at 1.05–1.20 to suppress racemization and metal precipitation. Isomerization proceeds at 80–120 °C for 4–12 h, followed by enamine hydrolysis and fractional distillation to isolate (R)-citronellal with enantiomeric excess above 97% ee. Residual rhodium in the distilled intermediate is reduced by acid washing and silica adsorption, with analytical verification against ICH Q3D(R2) Table A.2.2 parenteral PDE for rhodium of 10 µg/day where the final menthol is used in injectable formulations. Further processing includes acid-catalyzed cyclization of (R)-citronellal to isopulegol and hydrogenation over nickel-silica to (−)-menthol, which is crystallized or co-distilled with peppermint oil components. Pharmaceutical compliance for menthol as an excipient and active substance in oral dosage forms follows Ph. Eur. monograph 0406 for levomenthol and USP Menthol Monograph, while residual solvent requirements follow USP <467> and ICH Q3C(R8). Terminal finished product types include menthol-containing lozenges, enteric-coated peppermint oil capsules for irritable bowel syndrome, oral suspensions with mint flavor, and topical water-miscible menthol preparations; injectable levomenthol preparations are less common and published data for specific parenteral drug products is limited. The process constraint is oxygen exclusion during BINAP-Rh recycle because phosphine oxidation to BINAP oxide raises rhodium leaching and reduces isomerization selectivity.

The naproxen sodium route via BINAP-ruthenium asymmetric hydrogenation of 2-(6-methoxy-2-naphthyl)acrylic acid is operated in stainless-steel or Hastelloy stirred autoclaves with gas-induction impellers and external hydrogen recycle. In a typical preparative protocol, ruthenium precursor is combined with 1.05–1.15 molar equivalents of (R)-BINAP in degassed methanol at 40–60 °C, then charged to the prochiral α-arylpropenoic acid at a substrate-to-catalyst molar ratio between 200 and 1,000, corresponding to 0.1–0.5 mol% Ru-BINAP relative to substrate. The hydrogenation is maintained at 10–80 bar hydrogen and 25–60 °C until conversion exceeds 99% and enantiomeric excess exceeds 95% ee; residual ruthenium is subsequently reduced by silica-gel adsorption and carbon treatment to meet ICH Q3D(R2) Table A.2.2 oral daily exposure limits and parenteral PDEs where the API is diverted to injectable presentation. Compliance for API manufacturing follows ICH Q7 Section 12.1 for process validation and 21 CFR 211 for finished drug product GMP. After acidification with hydrochloric acid, (S)-naproxen is crystallized from aqueous methanol and dried at 50–70 °C under vacuum. The dried API is roller-compacted with microcrystalline cellulose and croscarmellose sodium at roll force 10–20 kN/cm, milled through a 0.8 mm screen, and blended in a bin blender for 15–25 min before rotary tablet compression at 40–80 rpm to hardness 80–150 N; capsules are filled on dosator machines at 1,000–2,400 capsules/min, and granules for suspension are sachet-filled after dry granulation. Terminal finished product types include naproxen sodium tablets at 220 mg, 275 mg, and 550 mg, naproxen capsules, and naproxen sodium oral suspension granules, while the injectable route is limited to clinical or hospital compounding rather than a standard commercial naproxen parenteral monograph in many jurisdictions.

What Limits Dynamic Kinetic Resolution in BINAP−Ru β-Keto Ester Hydrogenation?

Dynamic kinetic resolution in BINAP−Ru-catalyzed hydrogenation of racemic α-substituted β-keto esters is constrained by the balance between substrate racemization rate and catalyst turnover frequency. Industrial synthesis of syn-2-substituted-3-hydroxy esters for carbapenem side-chain intermediates uses ruthenium-BINAP complexes at substrate/catalyst ratios of 100 to 1,000, equivalent to 0.1–1.0 mol% Ru-BINAP, with ligand-to-ruthenium ratios of 1.1–1.3 to preserve chelate integrity during prolonged hydrogenation. The reaction is typically run in methanol or ethanol at 4–20 bar hydrogen and 40–80 °C; water content in solvent feed above 0.1 wt% is an observed failure mode in production autoclaves because it promotes ruthenium cluster formation and wall deposition on stainless steel surfaces. Under optimized conditions, diastereoselectivity exceeds 98:2 and enantiomeric excess exceeds 99% ee, after which the catalyst is removed by chelating silica or activated carbon filtration and the hydroxy ester is distilled or crystallized. Residual ruthenium is controlled to ICH Q3D(R2) Table A.2.2 limits: oral PDE 100 µg/day and parenteral PDE 10 µg/day. The 3-hydroxy ester building block is then coupled to azetidinone intermediates for carbapenem sodium injectable APIs, using aseptic crystallization, sterile filtration, and freeze-drying under EU GMP Annex 1 and 21 CFR 210/211. Finished injectable products are filled into Type I borosilicate glass vials under Grade A ISO 5 conditions and reconstituted with 0.9% sodium chloride injection before intravenous infusion. Terminal finished product types include carbapenem sodium vials for injection, oral sachet granules for carbapenem-based investigational oral prodrugs where applicable, and lyophilized powder units. Published data for the specific BINAP-Ru carbapenem side-chain configuration is limited; process validation batches require verification of ruthenium scavenger performance under current good manufacturing practice.

When Dehydroamino Acid Hydrogenation Supplies Chiral Amino Acid API

When (Z)-α-acetamidocinnamic acid and related dehydroamino acid derivatives are subjected to BINAP-rhodium asymmetric hydrogenation, the resulting N-acetyl amino acid building blocks can be advanced into synthetic peptide active pharmaceutical ingredients. The catalyst is prepared from a rhodium(I) precursor and (R,R)-BINAP at ligand-to-rhodium ratios of 1.1–1.3, then applied at substrate/catalyst molar ratios of 100 to 1,000, corresponding to 0.1–1.0 mol% rhodium-BINAP relative to the unsaturated substrate. Hydrogenation is performed at 1–10 bar hydrogen and 20–35 °C in tetrahydrofuran or methanol, with enantiomeric excess exceeding 98% ee for substituted aryl alanine derivatives. Residual rhodium is removed by adsorbent treatment and crystallization to comply with ICH Q3D(R2) Table A.2.2 parenteral PDE of 10 µg/day and oral PDE of 100 µg/day; API manufacturing is governed by ICH Q7 and finished peptide product GMP by 21 CFR 211. Downstream peptide production uses solid-phase synthesis on Wang or 2-chlorotrityl resins, followed by trifluoroacetic acid cleavage, preparative high-performance liquid chromatography, and lyophilization. Finished product types include injectable peptide vials containing lyophilized peptide with mannitol as bulking agent, enteric-coated peptide capsules for oral delivery, and granules for oral suspension where acid-labile peptides require pH-modulated release. Compliance for peptide injectables includes USP <71> sterility testing, USP <85> bacterial endotoxins, and USP <790> particulate matter for injectable products. Published data for specific BINAP-Rh dehydroamino acid routes in commercial peptide API manufacturing is limited, and each peptide development program must verify enantiomeric purity and residual rhodium in the isolated amino acid building block.

Ibuprofen Sodium Injection and Oral Dosage Form Route via α-Arylpropenoic Acid Reduction

For the ibuprofen sodium route, BINAP-ruthenium asymmetric hydrogenation of 2-(4-isobutylphenyl)acrylic acid provides (S)-ibuprofen after acidification and recrystallization. The catalyst is generated with (S)-BINAP and ruthenium acetate or chloride in methanol-water mixtures at 40–60 °C; BINAP-to-ruthenium molar ratio is held at 1.05–1.15, and the catalyst is charged at 0.05–0.2 mol% ruthenium-BINAP relative to substrate, corresponding to substrate/catalyst molar ratios of 500 to 2,000. Hydrogenation is conducted at 5–30 bar hydrogen and 20–50 °C, with conversion above 99% and enantiomeric excess above 97% ee. Residual ruthenium is reduced to ICH Q3D(R2) Table A.2.2 limits: oral PDE 100 µg/day, parenteral PDE 10 µg/day, with testing by USP <233>. API manufacture follows ICH Q7, while drug product manufacture follows 21 CFR 211 and USP Ibuprofen Monograph or USP Ibuprofen Injection Monograph as applicable. Downstream oral solid dosage processing includes roller compaction with pregelatinized starch and crospovidone, tablet compression at 40–80 rpm to hardness 80–150 N, capsule filling with 200 mg doses, and granule production for suspension with pH-adjusted vehicle. Injectable ibuprofen sodium is manufactured by aseptic dissolution, sterile filtration through 0.22 µm membrane filters, filling into Type I glass vials under Grade A ISO 5, and terminal sterilization at 121 °C for 15 min where the formulation is thermally stable. Terminal finished product types include ibuprofen tablets at 200 mg, 400 mg, 600 mg, and 800 mg, ibuprofen capsules at 200 mg, ibuprofen oral suspension granules at 100 mg/5 mL after reconstitution, and ibuprofen sodium injection concentrates at 100 mg/mL or other approved strengths.